

SCHEDULE OF EVENTS

Thursday, September 19, 2013

1500 – 2000 Registration

1430 – 1500 ISSTD Nominating Committee Meeting

1500 – 1730 ISSTD Executive Committee Meeting

1730 – 2000 ISSTD Reception

1830 – 1835 Welcome & Introduction, John Lurain, MD and Michael Seckl, MD

1835 – 1855 The UK Perspective on the History of GTD, Kenneth Bagshawe, MD

1855 – 1915 The NCI Experience in the Treatment of GTN, Charles Hammond, MD

1915 – 1930 Patient Experiences, Tigi Martin Dixon & Kerri Herman

Evening Events Dinner on own

Friday, September 20, 2013

Society of Gynecologic Oncology (SGO) State of the Art Symposium

0730 – 1730 Registration

0730 – 0800 Breakfast

0800 – 0810 Welcome and Introduction, Emily Berry, MD

0810 – 0920 Session I: The Foundation of GTN

0810 – 0830 Personal Perspective on the History of GTD, Donald Goldstein, MD

0830 – 0850 Pathology of Gestational Trophoblastic Disease, Michael Wells, MD

0850 – 0910 Genetics of GTD, Rosemary Fisher, MD

0910 – 0920 Questions, Moderator: LC Wong, MD

0920 – 1030 Session II: Molar Pregnancy

0920 – 0940 Clinical Features of Complete and Partial Moles, Ross Berkowitz, MD

0940 – 1000 Surgical Management of Hydatidiform Moles, John Tidy, MD

1000 – 1020	Complications of Hydatidiform Mole, Maria Stephanie Fay S. Cagayan, MD
1020 – 1030	Questions, Moderator: Rafael Cortes-Charry, MD
1030 – 1100	Morning Break
1100 – 1230	Session III: Staging and Definition of Postmolar GTN
1100 – 1120	FIGO Staging of GTD, Ernest Kohorn, MD
1120 – 1140	Diagnosis of Postmolar GTN: FIGO Definitions versus use of hCG Regression Curves, Leon Massuger, MD
1140 – 1200	Management of Low-level hCG's, Emily Berry, MD
1200 – 1230	Panel Discussion: Decision-making regarding hCG plateaus/low values Moderator: PK Sekharan, MD
1230 – 1330	Lunch
1330 – 1500	Session IV: Low-Risk GTN
1330 – 1345	Treatment of Low-Risk Gestational Trophoblastic Neoplasia, Raymond Osborne, MD
1345 – 1400	The UK Experience with MTX-FA for Treatment of Low-Risk GTN, Barry Hancock, MD
1400 – 1415	Changing Treatment in Low-Risk GTN, François Golfier, MD, PhD
1415 – 1430	GOG 0275, Julian Schink, MD
1430 – 1500	Case-based questions, Moderator: Vilmos Fülöp, MD, PhD, DSc
1500 – 1530	Afternoon Break
1530 – 1730	Session V: High-Risk GTN
1530 – 1545	Initial Chemotherapy for High-Risk GTN, Robert Coleman, MD
1545 – 1600	Salvage Therapy for High-Risk GTN, John Lurain, MD
1600 – 1615	Brain Metastases in GTN, Nikki Neubauer, MD
1615 – 1630	Treatment of Ultra-High-Risk GTN, Michael Seckl, MD
1630 – 1645	PSTT/ETT, Hextan Ngan, MD

1645 – 1700 Follow Up and Side Effects after Treatment of GTN, Philip Savage, MD, PhD

1700 – 1730 Case-based questions, Moderator: David Baartz, MD

1830 – 2200 Faculty Dinner (by invitation)

Evening on own

Saturday, September 21, 2013

ISSTD World Congress XVII

0730 – 1700 Registration

0730 – 0800 Breakfast

0800 – 0915 Plenary Session I: Experiences at GTN Referral Centers & Trophoblast Disease Registries

0800 – 0810 Introduction and Welcome

0810 – 0820 Epidemiological profile of patients with hydatidiform mole (HM) at a reference center (RC) in southern Brazil by E. Arlindo, E. Uberti, M. Fajardo, A. Cunha, M. Jimenez

0820 – 0830 Epidemiological report on the treatment of patients with gestational trophoblastic disease from 2000 to 2011 in Brazilian reference centers by E. Uberti, M. Fajardo, A. Braga, P. Belfort (in memoriam), MG. Viggiano et. al, S. Sun et al., A. Braga et al., M. Martins et al., B. Grillo SL, J. Andrade et al., C. B. Souza, Madi et al., I. Maestá et al., E. Silveira et al.

0830 – 0840 Trends in the chemotherapeutic management of gestational trophoblastic neoplasia in the Philippines by M. Cagayan, D. Arellano

0840 – 0850 Quebec trophoblastic disease registry: A 4-year collaborative experience and canadian perspectives by P. Sauthier, M. Breguet, K. Rahimi, M. Martin, N. Letarte, R. Slim

0850 – 0911 Poster Review I: Experiences at GTN Referral Centers

Poster 1: Treatment of gestational trophoblastic neoplasia at the center for trophoblastic diseases, 33rd Ward (maternity), Santa Casa da Misericórdia, Rio de Janeiro by F. Asmar, O. Vale, V. Moraes, P. Dantas, C. Novaes, J. Amim, J. Rezende, A. Braga

Poster 2: Correlation between the clinical and histopathological forms of GTD with the symptomatology of patients at the center for trophoblastic diseases, 33rd Ward (maternity), Santa Casa da Misericórdia, Rio de Janeiro by F. Asmar

Poster 3: Gestational trophoblastic neoplasia: A 16-year experience by C. Jacobs, K. Chrystal, P. Fong, B. Evans

Poster 4: Queensland Trophoblast Centre (QTC) by S.J. Morrison, M. Eddy, K. Sanday, A. Garrett

Poster 5: Epidemiology of cases seen at the referral center of gestational trophoblastic disease (GTD) at Antonio Pedro by N. Guenther, A. Ferreira, D. Monteiro, A. Pires, L. Marcolino, V. Moraes, C. Lozoya, F. Vasques, A. Braga

Poster 6: Gestational trophoblastic disease: clinical trends over 12 years at a Venezuelan referral center by R. Cortés-Charry, A. Salazar, L. Rodríguez, L. Ruíz

Poster 7: A multicenter analysis of gestational trophoblastic neoplasia in Turkey by S.Sinan Ozalp, G.Tulunay, N. Boran, T.Turan, K. Yuce, V. Ulker, M.Sanci, M.Gokcu, G.Tosun, Y. Dikmen, A. Ozsaran, M. C. Terek, L. Akman, H. Yetimlar, T. Gungor, E. Ozgu, Y. Yıldız, A. Kokcu, M. Kefeli, S. Kuruoglu, H.Yuksel, D. Arioç, N. Tuncer, H. Bozkaya, S. Guven, D. Kulaksiz, F.Varol, M. Api, K.Guzin, E.Caliskan, E. Doger, B.Cakmak

0911 – 0915 Q&A

0915 – 1000 Break and View Posters

1000 – 1215 Plenary Session II: Genetics and Molecular Pathways

1000 – 1005 Introduction

1005 – 1015 Hydatidiform moles and tetraploidy by L. Sunde, L. Sundvall, I. Niemann, H. Lund, U. Jensen, L. Bolund

1015 – 1025 NLRP7 or KHDC3L are not common causes of mosaic moles, non-familial biparental moles, hydatidiform mole plus recurrent miscarriages, familial androgenetic, or recurrent androgenetic hydatidiform moles by L. Andreassen, O.B. Christiansen, I. Niemann, L. Bolund, L. Sunde

1025 – 1035 Risk of recurrent hydatidiform mole after complete or partial molar pregnancy by R. Fisher, N. Sebire, N. Eagles, D. Short, P. Savage, M. Seckl

1035 – 1045 The gene expression of HIF-1 α mRNA in the pathogenesis of the progression of complete hydatidiform mole to gestational trophoblastic neoplasia (GTN) by R. Perbawati, A. Harsono, H. Susanto

1045 – 1055 Analysis of Syncytin-1 protein interaction network in gestational trophoblastic diseases malignant transformation by P. Bolze, F. Mallet, S. Patrier, F. Golfier

1055 – 1105 Endoglin as a potential target for the treatment of gestational trophoblastic neoplasia by K. Elias, K. Hasselblatt, S. Ng, R. Berkowitz, N. Horowitz

- 1105 – 1115 The effect of ethinyl estradiol and desogestrel on proliferation and apoptosis in hydatidiform mole trophoblast cells by I. Sasteradinata, W. Lelly, Sri Hartini, B. Sutrisna
- 1115 – 1125 p-21-Activated Kinase-1, -4 and -6 and estrogen receptor expression pattern in normal placenta and gestational trophoblastic diseases by M. Shoni, Z. Nagymanyoki, A. Vitonis, J. Cynthia, SW. Ng, B. Quade, R. Berkowitz
- 1125 – 1135 Type I interferon signaling controls methotrexate resistance in choriocarcinoma by K. Elias, K. Hasselblatt, M. Sclanders, S. Ng, O. Pardo, M. Seckl, R. Berkowitz
- 1135 – 1145 Absence of KHDC3L mutations in Chinese patients with recurrent and sporadic hydatidiform moles by J. Qian, W. Zhao, C. Qi, R. Slim
- 1145 – 1155 Choriocarcinoma genomic alterations associated with clinical outcome by J. Mello, I. Maestá, A. Tavares, M. Domingues, M. Rudge, S. Rogatto
- 1155 – 1205 NLRP7, a NOD-like receptor protein, is required for normal cytokine secretion and co-localizes with the Golgi and the microtubule organizing center by R. Slim, C. Messaed, E. Akoury, U. Djuric, J. Zeng, M. Seoud

1215 – 1315 Lunch

1315 – 1445 Plenary Session III: Molar Pregnancy

- 1315 – 1320 Introduction
- 1320 – 1330 The clinical epidemiology and management of hydatidiform mole at the Santa Casa da Misericórdia of Rio de Janeiro reference center in Brazil: 54-years of experience by J. Rezende-Filho, O. Vale, D. Munene, V. Moraes, C. Novaes, J. Amin-Júnior, A. Braga
- 1330 – 1340 Hydatidiform mole clinical characteristics and outcomes in adolescents: A study in South American centers by R. Soares, I. Maestá, J. Colón, A. Braga, A. Salazar, R. C. Charry
- 1340 – 1350 Incidence of hydatidiform mole in Denmark 1999 – 2010 by H. Lund, A. Grove, M. Vyberg, L. Sunde
- 1350 – 1400 Influence of race on type and severity of hydatidiform mole by L. Felder, M. Worley, S. Ng, SW. Ng, D. Goldstein, R. Berkowitz, N. Horowitz
- 1400 – 1410 Clinical usefulness of immunohistochemical staining of p57kip2 for the differential diagnosis of complete mole by S. Sasaki, Y. Sasaki, A. Sekizawa, T. Kunitamura, Y. Kojima, K. Iino
- 1410 – 1420 Short repeat tandem assay refines the diagnosis of hydatidiform moles by S. Patrier, F. Marguet, A. Lamy, M. Crahes, J.C. Sabourin, P. Bolze, F. Golfier
- 1420 – 1430 CGH+SNP microarray analysis of complete and partial hydatidiform moles by

U. Surti, L. Hoffner

1430 – 1440 p57 kip2 immunohistochemistry: Ancillary technique in hydatidiform moles diagnosis by R. Cortés-Charry, J. Fernández, V. García, P. Dabed, A. Salazar, A. Pulido

1440 – 1445 Q&A

1445 – 1515 Break and View Posters

1515 – 1640 Plenary Session IV: Clinical Features, Risk Factors & Complications of Hydatidiform Moles

1515 – 1520 Introduction

1520 – 1530 Hydatidiform mole clinical characteristics, initial treatment and outcomes in women of advanced age: A study in South American centers by C. C. F. Desmarais, I. Maestá, J. Colón, A. Braga, M. Bianconi, G. Jankilevich, A. Salazar, R. Charry

1530 – 1540 Current clinical features of complete and partial hydatidiform mole in Sweden by U. Joneborg, L. Marions

1540 – 1550 Women with a partial mole during their first pregnancy and diagnosed earlier in gestation are at increased risk of developing gestational trophoblastic neoplasia by M. Worley, Jr., N. Joseph, R. Berkowitz, DP. Goldstein

1550 – 1600 Histopathological and immunohistochemical features of early hydatidiform moles in relation to subsequent development of persistent gestational trophoblastic disease by N. Sebire, G. Petts, R. Fisher, D. Short, I. Lindsay, M. Seckl

1600 – 1610 Malignancy risk factors of hydatidiform moles by H. Pradjatmo, D. Dasuki

1610 – 1620 Modern hormonal contraceptive use before hCG remission does not increase the risk of persistent trophoblastic disease (PTD) following complete hydatidiform mole (CHM) by A. Braga, D. Short, M. Izildinha, P. Savage, R. Harvey, M. Seckl

1620 – 1630 Frequency of persistent gestational trophoblastic disease (PTD) after spontaneous normalisation of hCG following a hydatidiform molar (HM) pregnancy by C. Coyle, D. Short, L. Dayal, L. Horsley, N. Sebire, B. Kaur, R. Harvey, P. Savage, M. Seckl

1630 – 1636 Poster Review II: Complications of Molar Pregnancy

Poster 8: A successful outcome of a molar pregnancy complicated by potentially life-threatening hyperthyroidism and ovarian hyperstimulation syndrome by J. Coulter, M. O' Riordan, P. Kelly

Poster 9: Subclinical hyperthyroidism in a population with molar pregnancy by R. Cortés-Charry, A. Salazar, A. Maldonado, J. Fernández, G. Montero, A. Borges

1700 – 1900 European Organisation for Treatment of Trophoblastic Diseases Meeting

Sunday, September 22, 2013

ISSTD World Congress XVII

0700 – 1600 **Registration**

0700 – 0730 **Breakfast**

0730 – 0915 **Plenary Session V: Twin Moles & hCG**

0730 – 0740 Introduction

0740 – 0750 Hydatidiform mole with a live fetus: A series of 26 patients by A. Braga, J. Amim Júnior, J. Rezende-Filho, I. Maestá, A. Maria Vieira de Camargo Martins, S. Sun, R. Souza, A. Salazar, R. Cortés-Charry

0750 – 0800 Update on UK outcomes for women with twin pregnancies comprising a complete hydatidiform mole (CHM) and normal co-twin by I. Niemann, R. Fisher, N. Sebire, M. Wells, D. Short, J. Tidy, B. Hancock, R. Coleman, P. Savage, M. Seckl

0800 – 0810 Human chorionic gonadotropin regression in non molar pregnancy: A preliminary study by R. Cortés-Charry, N. Corredor, N. García, J. Fernández, A. Salazar, M. Fargioni

0810 – 0820 Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia (GTN) by I. Maestá, W. Growdon, D. Goldstein, M. Bernstein, N. Horowitz, M. Rudge, R. Berkowitz

0820 – 0830 Utility of serum human chorionic gonadotropin free β -subunit (hCG β) measurement in the management of gestational trophoblastic neoplasia (GTN) by R. Harvey, P. Wardell, R. Caser-Lahoy, N. Sebire, D. Short, P. Savage, M. Seckl

0830 – 0840 Risk of gestational trophoblastic neoplasia after hCG normalisation according to hydatidiform mole type by J. Massardier, C. Schmitt, P. Bolze, T. Hajri, A. Schott, B. You, S. Patrier, M. Doret, D. Raudrant, F. Golfier

0840 – 0850 Time to hCG normalisation in patients with hydatidiform molar pregnancy (HM) and risk of persistent gestational trophoblastic disease (PTD) by C. Coyle, D. Short, L. Dayal, L. Horsley, N. Sebire, B. Kaur, R. Harvey, P. Savage and M. Seckl

0850 – 0900 Comparative analysis of hCG kinetic profiles in a large international pooled cohort of patients with low-risk gestational trophoblastic neoplasia (GTN) treated with 3 different treatment regimens by B. You, O. Colomban, R. Harvey, M. Seckl, R. Osborne, F. Golfier

0900 – 0915 Q&A

0915 – 0945 Break and Visit Posters

0945 – 1205 Plenary Session VI: Low-risk GTN

- 0945 – 0950 Introduction
- 0950 – 1000 Actinomycin D for the treatment of low risk gestational trophoblastic neoplasia in Brisbane, Queensland: A change in institution policy by A. Garrett, K. Sanday, S. Morrison, D. Baartz, J. Eddy
- 1000 - 1010 Peroral methotrexate as initial treatment for postmolar gestational trophoblastic neoplasia regardless of risk group: A 30-year experience at Aarhus University Hospital, Denmark by L. Faaborg, J. Lindegaard, I. Niemann
- 1010 – 1020 Which chemotherapy regimen do women prefer for low-risk GTN: A survey and derivation of utility values by C.J. Reade, L.R. Eiriksson, R. Osborne, N.T. Shah, J. Dodge, F. Moens, R. Goeree
- 1020 – 1030 Chemotherapy for low-risk GTN: A probabilistic decision analysis model by C.J. Reade, R. Osborne, N. Shah, L.R. Eiriksson, J. Dodge, F. Moens, R. Goeree
- 1030 – 1040 Treatment of low-risk gestational trophoblastic neoplasia (GTN): A single institution and original cohort study comparing two single-agent chemotherapy regimens: Biweekly use of eight-day high-dose Methotrexate plus folinic acid rescue and pulsed Actinomycin-D by E. Uberti, M. Carmo Fajardo, A. Gerhardt Vieira da Cunha, S. Ribeiro Ferreira, S. Soares Frota, A. Celso Koehler Ayub
- 1040 – 1050 Low risk gestational trophoblastic neoplasia (GTN) first attempt resistant to treatment: Is polichemotherapy needed? by S. Otero, M. Bianconi, C. Alvarez L. Storino, G. Jankilevich
- 1050 – 1100 Etoposide and dactinomycin as second-line low risk treatment for Gestational Trophoblastic Neoplasia: A decade of experience at the Sheffield Centre for Trophoblastic Disease, United Kingdom by M. Winter, J. Everard, F. Khan, J. Tidy, B. Hancock, R. Coleman
- 1100 – 1110 Single agent carboplatin as second-line therapy for methotrexate-resistant gestational trophoblastic neoplasia by R. Coleman, J. Cook, A. Hills, S. Gillett, J. Tidy, M. Winter
- 1110 – 1120 How to treat patients with low-risk GTN FIGO score 5-6 by T. Kanno, H. Matsui, M. Kihara, H. Usui, M. Shozu
- 1120 – 1130 A review of the management and outcomes of patients with low risk GTN treated in Sheffield, UK from 1997 to 2006 by M. Macdonald, B. Hancock, M. Winter, R. Coleman, J. Tidy

1130 – 1140	Barriers and solutions to activating an international phase III randomized trial of low-risk gestational trophoblastic neoplasia (GTN): The GOG 275 experience by <u>J. Schink</u> , J. Tidy, M. Seckl, R. Osborne, J. Carter, V. Filiaci, H. Huang, D. Miller
1140 – 1150	Patients treated for low-risk GTN in Sheffield, UK from 1997 to 2006: A comparison of management and outcomes of patients with Stage I and Stage III disease by <u>M. Macdonald</u> , B. Hancock, M. Winter, R. Coleman, J. Tidy
1150 – 1200	The utility of uterine pulsatility index (UAPI), hCG isoforms and angiogenic factors in predicting methotrexate (MTX) resistance in low-risk gestational trophoblastic neoplasia (GTN) by <u>R. Harvey</u> , M. Papadaki, R. Fisher, N. Sebire, D. Short, P. Savage, U. Stenman, T. Grönholm, R. Agarwal, M. Seckl
1200 – 1205	Q&A
1205 – 1300	Lunch
1300 – 1420	Plenary Session VII: Reproductive Outcomes
1300 – 1305	Introduction
1305 – 1315	Anti-mullerian hormone (AMH) levels in patients treated with chemotherapy for gestational trophoblastic neoplasia (GTN): Is it a reliable assessment of fertility following treatment? by <u>R. Ramaswami</u> , P. Savage, M. Seckl
1315 – 1325	Reproductive outcomes after multiagent chemotherapy for high-risk gestational trophoblastic neoplasia by <u>J. Wong</u> , D. Liu, J. Schink, J. Lurain
1325 – 1335	Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia: Updated results by <u>R. Vargas</u> , L. Diver, L. Barroilhet, K. Esselen, L. Garrett, M. Bernstein, D. Goldstein, R. Berkowitz
1335 – 1345	The effects of chemotherapy treatment for gestational trophoblastic tumours on second tumour risk and early menopause by <u>P. Savage</u> , R. Cook, J. O’Nions, J. Krell, A. Kwan, M. Camarata, G. Dancy, D. Short, A. Swerdlow, M. Seckl
1345 – 1355	The impact of body mass index (BMI) on the clinical presentation and outcomes of women with gestational trophoblastic neoplasia (GTN) by J. Moulder, A. Vitonis, Berkowitz, D. Goldstein, M. Bernstein, <u>N. Horowitz</u>
1355 – 1405	The effect of early pregnancy following chemotherapy on disease relapse and fetal outcome in women treated for gestational trophoblastic neoplasia (GTN) by <u>J. Williams</u> , D. Short, L. Dayal, S. Strickland, R. Harvey, T. Tin, P. Savage, M. Seckl
1405 – 1415	Recommendations of the European Organisation for Treatment of Trophoblastic Diseases about management of gestational trophoblastic diseases by P. Bolze, <u>J. Attia</u> , J. Massardier, M. Seckl, L. Massuger, N. van Trommel, T. Hajri, A. Schott, F. Golfier

1415- 1420	Q&A
1420 – 1450	Break and View Posters
1450 – 1540	Plenary Session VIII: Chemotherapy for High-risk GTN
1450 – 1455	Introduction
1455 – 1505	Role of Capecitabine in the management of Gestational Trophoblastic Neoplasia (GTN): A drug for two settings by <u>M. Bianconi</u> , S. Otero, C. Torino, G. Jankilevich
1505 – 1515	Changes in the management of high risk GTN in the National Trophoblastic Disease Center of Hungary by <u>V. Fülöp</u> , I. Szigetvári, J. Szepesi, G. Végh, R. Berkowitz
1515 – 1525	The effectiveness of TP/TE & EMA-EP regimens as salvage chemotherapy in patients of refractory or recurrent gestational trophoblastic tumors by S. Jung, M. Choi, H. Park, J. Lee, Y. Hwang, C. Lee, <u>J. S. Geun</u>
1525 – 1535	An update of TE/TP activity in EMA/CO failures and the plan for a TE/TP vs. EP/EMA trial by <u>M. Seckl</u> , D. Short, J. Warwick, R. Harvey, N. Sebire, B. Kaur, S. Strickland, J. Reise, P. Savage
1535 – 1540	Q&A
1730 – 2200	Architectural Boat tour and dinner at the Langham Hotel

Monday, September 23, 2013

ISSTD World Congress XVII

0730 – 1200	Registration
0730 – 0800	Breakfast
0800 – 0930	Plenary Session IX: Metastatic Disease & Choriocarcinoma
0800 – 0805	Introduction
0805 – 0815	Brain metastases in gestational trophoblast tumors: An update on incidence, management and outcome by <u>P. Savage</u> , I. Kelpandides, M. Tuthill, D. Short, M. Seckl
0815 – 0825	Pulmonary metastases: A negative influence on prognosis in gestational trophoblastic disease? by <u>M. Vree</u> , N. van Trommel, L. Massuger, F. Sweep, G. Kenter, C. Thomas, C. Lok
0825 – 0835	Vaginal metastases in gestational trophoblastic disease: Low risk or not? by <u>M. Vree</u> , C. Lok, L. Massuger, F. Sweep, M. Kate-Booij

- 0835 – 0845 Hepatic metastases in gestational trophoblastic neoplasia: Patient characteristics, prognostic factors and outcomes by E.L. Barber; J. Schink, J. Lurain
- 0845 – 0855 Evaluating response to first line treatment in term and non-term choriocarcinoma by C. Milligan, R. Coleman, J. Tidy, B. Hancock
- 0855 – 0905 Changes in clinical presentation of postterm choriocarcinoma at the a regional referral center in recent years by E. Diver, T. May, R. Vargas, M. Bernstein, D. Goldstein, R. Berkowitz
- 0905 – 0915 Fatal Gestational Choriocarcinoma: An Analysis of Treatment Failures from 1979-2012 Compared to 1962-1978 by N. Neubauer, A. Strohl, J. Schink, J. Lurain
- 0915 – 0927 Poster Review III: ETT & Choriocarcinoma

Poster 10: Positron emission tomography imaging in restaging recurrent epithelioid trophoblastic tumor by E. Zsiros, S. Jean, S.C. Rubin

Poster 11: Combined modality therapy of metastatic epithelioid trophoblastic tumor: A report of two cases by E. Berry, A. Hoekstra, J. Lurain

Poster 12: Choriocarcinoma diagnosed 22 years after spontaneous remission of a complete hydatidiform mole: A case report by EH. Uberti, MC. Fajardo, AG. Vieira da Cunha, G. de Napoli, JP. Furtado, JJP. Camargo

Poster 13: Partial hysterectomy as a treatment for patients with gestational choriocarcinoma and chemoresistance: Two cases from the French Trophoblastic Disease Center by J. Massardier, F. Couder, P. Bolze, B. You, V. Trillet-Lenoir, M. Devouassoux, M. Leheuteur, M. Quemere, T. Hajri, D. Raudrant, A. Schott, F. Golfier

- 0927 – 0930 Q&A

0930 – 1000 Break & View Posters

1000 – 1120 Plenary Session X: PSTT

- 1000 – 1005 Introduction
- 1005 – 1015 Prognostic markers of recurrence for patients with stage I placental site trophoblastic tumor by X. Yi, L. Bao
- 1015 – 1025 PSTT: A diagnostic and therapeutic challenge by U. Joneborg, L. Marions
- 1025 – 1035 Placental site trophoblastic tumor: Clinical presentation, pathology, treatment and prognosis by J. Zhao, Y. Xiang, X.R. Wan, F.Z. Feng, T. Ren L.N. Guo

1035 – 1045	Placental site and epithelioid trophoblastic tumors: A series of 22 patients by <u>F. Golfier</u> , A. Moutte, T. Hajri, N. Peyron, F. Chateau, J. Massardier, P. Bolze, P. Duvillard, S. Patrier, A. Schott, J. Attia, B. You, D. Raudrant
1045 – 1055	An innovative morphological MRI classification of placental site trophoblastic tumors by <u>F. Golfier</u> , N. Peyron Faure, P. Rousset, F. Chateau, L. Frappart, F. Réty
1055 – 1105	Atypical placental site nodule (APSN): A clinicopathological study of 21 cases by <u>B. Kaur</u> , D.Short, M. Seckl, P. Savage, R.Harvey, F.Rosemary, N. Sebire
1105 – 1115	The ISSTD global placental site and epithelioid trophoblastic tumour (PSTT/ ET'T) database: An analysis of the first 210 patients by <u>B. Hancock</u> , A. Burnett, R. Berkowitz, D. Goldstein, F. Golfier, L. Massuger, N. van Trommel, Y.Chen, P. Sauthier, R. Coleman, J. Tidy, P. Savage, L. Ellis, D. Short, S. Mori, J. Horsman, M. Bernstein, R. Smith, N. Sebire, M. Wells, M. Seckl
1115 - 1120	Q&A
1120 – 1150	International Society for the Study of Trophoblastic Diseases General Assembly
1150 – 1155	Awards Presentation for Outstanding Oral and Poster Presentations
1155 – 1205	Concluding remarks
1210	Course concludes